We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


SBS Announces Keynote Speakers at its 13th Annual Conference

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SBS Announces Keynote Speakers at its 13th Annual Conference"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

This dynamic threesome will give attendees insights to ponder as well as to enhance their careers. 

Dr. Larry Gold, along with David Brunel founded SomaLogic, Inc. of Boulder, Colorado. He is currently the Chief Executive Officer, Chief Science Officer and Chairman of the Board.  The company builds proteomic “chips” for post-genomic life science research and clinical diagnostics. 

Dr. Gold was the founder of NeXstar Pharmaceuticals, Inc. and served as Director from its inception in 1991, and as Chairman of the Board and Chief Scientific Officer from February 1993 until July 1999.  Along with three others, he also founded Synergen in 1981.

Starting as a professor at the University of Colorado at Boulder ("CU") in 1970, Dr. Gold later served as Chairman of the Department of Molecular, Cellular and Developmental Biology from 1988 to 1992. 

Today, Dr. Gold has only minor responsibilities at CU.  He was awarded the Chiron prize for Biotechnology in 1995 and is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.

Julian Davies is Emeritus Professor of Microbiology and Immunology at the University of British Columbia; Vancouver, BC.  Recently he was Director of the UBC Life Sciences Institute.  Although trained as an organic chemist in Britain, he discovered microbiology in 1962. 

After holding faculty positions at Harvard and the University of Wisconsin, Prof. Davies joined the biotechnology company Biogen as Director of Research and held this position until 1985.

He then returned to academia and held positions as Professor of Biotechnology at the Institut Pasteur in Paris and Head of the Department of Microbiology and Immunology at UBC. 

Prof. Davies was the founder of TerraGen the first company to apply metagenomics to drug discovery, and then Executive VP of Cubist Pharmaceuticals, Inc. following their acquisition of TerraGen. 

Prof. Davies has consulted for a number of pharmaceutical companies.  He has been President of the American Society of Microbiology and President of the International Union of Microbiological Societies and has received a number of awards and honors.  He is a Fellow of the Royal Society of London and the Royal Society of Canada. 

The title of his presentation is “Everyone depends on everyone else.”

Dr. Eugene Butcher is a professor in the Department of Pathology at Stanford University, a staff physician of the Palo Alto Veterans Affairs Health Care System, and co-founder and Chair of the Scientific Advisory Board of Bioseek, Inc.

He was scientific co-founder and co-chair of the Scientific Advisory Board of Leukosite, Inc. (now merged with Millennium Pharmaceuticals) and has served on the Scientific Advisory Boards of Millennium, Medimmune, and Thios Pharmaceuticals. 

He received a B.S. in Chemistry from the Massachusetts Institute of Technology and an M.D. from the Washington University School of Medicine, St. Louis, Missouri.

Dr. Butcher has been elected to the American Association of Physicians, and has been awarded the Warner Lambert/Parke Davis Award by the American Association of Pathologists, the AAI-Huang Foundation Meritorious Career Award by the American Association of Immunologists, and an Outstanding Inventor Award from Stanford University. 

He received the Crafoord Prize from the Swedish Academy of Sciences in 2004 for the scientific discovery of mechanisms of leukocyte trafficking contributing to the treatment of arthritis and inflammatory diseases. 

His tentative presentation is titled “Human cell systems biology for drug discovery: applications to drug innovation and development from screening to clinical indication selection.”